Danaher (DHR) DIvidends Date & History

Key Takeaways

• Danaher (DHR) pays a quarterly dividend of $0.40 per share, equal to a $1.60 annual payout.
• The dividend yield is modest, sitting at roughly 0.7%, well below the broader market and the healthcare industry median.
• Dividend sustainability is exceptional: the payout consumes only about 26% of earnings and under 20% of free cash flow.
• Danaher has paid a dividend for roughly 24 consecutive years and recently raised its payout by 25%.
• The stock appeals mainly to dividend growth and long-term investors, not to income-focused investors seeking high current yield.

Dividend Overview

Danaher Corporation, a global leader in life sciences, diagnostics, and biotechnology tools, maintains a consistent quarterly dividend policy. The company currently pays $0.40 per share each quarter, bringing its annualized dividend to $1.60 per share. Based on a share price in the low-to-mid $200s, this translates into a dividend yield of approximately 0.7%.

Danaher is best described as a dividend growth stock rather than a high-yield stock. Its yield is deliberately kept small so that the vast majority of its substantial free cash flow can be reinvested into acquisitions, research and development, and share repurchases. Payments are made quarterly, with recent ex-dividend dates falling in late March, June, September, and December and corresponding payments distributed in the following month. For dividend investors, Danaher represents a quality compounding franchise that returns a modest but steadily growing slice of cash to shareholders.

Dividend History and Growth

Danaher has a long track record of returning cash to shareholders, having paid a dividend for roughly 24 consecutive years. Over that period, the company has consistently prioritized gradual, reliable increases over large one-time jumps, reflecting its commitment to building shareholder value through disciplined capital allocation.

The most recent meaningful change came in early 2026, when the board raised the quarterly dividend from $0.32 to $0.40 per share — a 25% increase. Over the trailing five-year period, Danaher's dividend has grown at a compound annual rate of roughly 13%, a healthy pace for a company of its size. While the dividend has not grown in every single calendar year, the long-term trend is clearly upward, and the company's dividend growth streak reflects a management philosophy that pairs a low base payout with room for future increases.

Dividend Sustainability and Payout Ratio

Danaher's dividend is exceptionally well covered. The company's earnings payout ratio stands at roughly 26%, meaning only about a quarter of its net income is directed toward the dividend. Even more importantly, the dividend consumes less than 20% of its free cash flow — the actual cash generated after capital expenditures. This leaves a substantial cushion to protect the payout during economic downturns.

The underlying business reinforces this stability. Danaher generated approximately $5.5 billion in free cash flow over the trailing twelve months, many times the roughly $1.1 billion required to fund its entire annual dividend. A diversified portfolio spanning bioprocessing, laboratory instruments, and diagnostic testing reduces reliance on any single product cycle. Combined with a manageable debt profile and strong operating margins, the dividend is widely regarded as among the safest in the market, with ample room for continued growth.

Dividend Compared to Industry Peers

Within the healthcare and life sciences tools sector, Danaher's dividend yield of about 0.7% sits below the industry median, which typically ranges from roughly 1.3% to 1.8%. Several peers with similarly diversified, cash-generative business models also carry sub-1% yields, underscoring that this is a sector where capital is often prioritized toward innovation and acquisitions rather than large cash distributions.

What Danaher sacrifices in yield, it tends to compensate for through dividend growth and financial strength. Its low payout ratio and robust free cash flow give it greater flexibility to raise the dividend over time compared with higher-yielding peers that may be distributing a larger share of earnings. For investors, Danaher's profile is closer to a blue-chip dividend grower than an income vehicle — a distinction that matters when evaluating it against competitors in the diagnostics and life sciences space.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is especially useful for identifying dividend stocks, income-focused investments, trending stocks, breakout candidates, and other market opportunities more efficiently than manual screening. Whether you are hunting for steady dividend payers or high-growth names, the AI Screener can help you narrow the field with greater speed and precision.

Is This Stock Attractive for Dividend Investors?

Danaher is best suited to dividend growth investors and long-term, buy-and-hold investors who prioritize total return and financial strength over immediate income. Its sub-1% yield makes it a poor fit for income-focused investors or retirees who depend on their portfolio to generate spendable cash today. At the same time, the low payout ratio, strong free cash flow, and 25% recent dividend increase make it appealing to those seeking a dividend that can compound meaningfully over a decade or more.

Conservative investors may also appreciate the resilience of Danaher's diversified healthcare and life sciences franchise, which provides a high degree of confidence in the dividend's continuity even during economic stress. However, investors should weigh the modest yield against the stock's premium valuation and its reliance on continued earnings growth. Overall, Danaher is best viewed as a quality dividend grower for patient, growth-oriented investors rather than a dependable source of high current income.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations